Biotechnology Sector-Specific Regulatory Environment: As a clinical-stage biotechnology company, ANAB is highly sensitive to FDA approvals, clinical trial outcomes, and changes in drug development regulations, which directly impact its product pipeline and commercialization potential.

Interest Rates and Capital Availability: Biotech companies frequently require significant capital for research and development. Elevated interest rates can increase borrowing costs and reduce investor appetite for speculative growth stocks, affecting ANAB's ability to fund its pipeline and execute strategic initiatives.

Overall Economic Health and Healthcare Spending: While a clinical-stage company, broad economic trends and healthcare spending patterns can influence investor sentiment towards the healthcare sector and the willingness of larger pharmaceutical partners to engage in collaborations or licensing agreements for ANAB's therapeutic candidates.